Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 2 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 2 21.
ORTHO TRI-CYCLEN vs ORTHO-NOVUM 2-21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined estrogen-progestin oral contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing gonadotropin release. Additionally, induces changes in cervical mucus and endometrium.
FDA-approved: Prevention of pregnancyOff-label: Treatment of acne vulgaris, management of menstrual disorders
Prevention of pregnancy in women who elect to use oral contraceptivesTreatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications and have achieved menarche
One tablet (norgestimate 0.180-0.215-0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
One tablet orally once daily for 21 days followed by 7 days off. Each tablet contains norethindrone 2 mg and ethinyl estradiol 0.1 mg.
None Documented
None Documented
Norethindrone: ~8 hours (terminal). Ethinyl estradiol: ~12-15 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Norethindrone: terminal half-life 5-12 hours; ethinyl estradiol: terminal half-life 7-20 hours (enterohepatic recirculation may prolong effect). Steady-state achieved after 5-7 days.
Ethinyl estradiol: primarily metabolized by CYP3A4; norgestimate: rapidly hydrolyzed to norelgestromin (active) then levonorgestrel, metabolized by CYP3A4 and CYP2C9.
Ethinyl estradiol is metabolized primarily via CYP3A4, with contributions from CYP2C9 and CYP2C19. Norethindrone is metabolized via CYP3A4 and reduction pathways.
Norethindrone: 60-80% renal (as metabolites), 20-40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Biliary excretion contributes to fecal elimination.
Renal (approx. 60% as metabolites), fecal (approx. 40% as metabolites). Norethindrone and ethinyl estradiol are extensively metabolized; less than 5% excreted unchanged in urine.
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
Norethindrone: ~60% bound to albumin, ~1.5% to SHBG; ethinyl estradiol: ~97% bound to albumin (not to SHBG).
Norethindrone: 3-4 L/kg (large distribution into tissues, including breast and reproductive tissues). Ethinyl estradiol: 2-3 L/kg (distributes widely).
Vd for norethindrone: ~3.1±0.5 L/kg; for ethinyl estradiol: ~3.5–4.5 L/kg. Indicates extensive tissue distribution.
Norethindrone: ~65% (oral). Ethinyl estradiol: ~40-45% (oral) due to first-pass metabolism.
Oral: norethindrone ~64% (first-pass metabolism reduces it); ethinyl estradiol ~38-48% (high first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (GFR <30 mL/min); use alternative contraception.
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 mL/min) or dialysis, use is not recommended due to potential fluid retention and hypertension.
Contraindicated in patients with acute hepatitis, cholestatic jaundice of pregnancy or prior OCP use, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A/B; dose adjustment not defined but consider lower estrogen options.
Contraindicated in acute or chronic hepatocellular disease with abnormal liver function, including Child-Pugh class B or C. Adjustment not applicable in mild hepatic impairment (Child-Pugh class A) but use caution and monitor.
Not indicated in prepubertal children. Postmenarchal adolescents: same dosing as adults. Safety and efficacy not established in children <18 years.
Not indicated for use before menarche. After menarche, dosing is same as adult (one tablet daily for 21 days, then 7 days off). Weight-based guidelines are not established.
Not indicated for use after menopause. No specific geriatric dosing; contraindicated in postmenopausal women.
Not indicated for postmenopausal women. No specific geriatric dosing adjustments have been studied.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use. Risk increases with age and number of cigarettes smoked, especially in women over 35.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use oral contraceptives should be strongly advised not to smoke.
["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign/malignant)","Gallbladder disease","Hypertension","Carbohydrate/lipid effects","Hereditary angioedema","Chloasma","Retinal thrombosis","Depression"]
["Thrombotic events (venous and arterial)","Cardiovascular risks in smokers over 35","Hepatic neoplasia","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism effects","Ocular lesions (retinal thrombosis)","Reduced efficacy with hepatic enzyme inducers"]
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Undiagnosed abnormal genital bleeding","Pregnancy","Active liver disease or benign/malignant liver tumors","Hypersensitivity to any component","Heavy smoking in women over 35"]
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer or estrogen-dependent neoplasia","Hepatic adenoma or carcinoma (current or history)","Jaundice or liver disease (acute or chronic)","Hypersensitivity to any component","Smoking in women over 35 (<15 cigarettes/day is relative; >15 is absolute)"]
Data Pending Review
Data Pending Review
No specific food restrictions. Grapefruit may slightly increase estrogen levels; avoid large amounts. Alcohol consumption may increase hepatic toxicity risk; limit to moderate intake.
No specific food restrictions; grapefruit juice may alter estrogen metabolism but clinical significance is unclear. Maintain consistent diet to avoid GI upset. Avoid excessive alcohol intake.
Contraindicated in pregnancy. First trimester: associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of major malformations, but may cause fetal harm due to hormonal effects; use only if clearly needed.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of cardiovascular and limb reduction defects. Second and third trimesters: Associated with feminization of male fetuses and potential for other teratogenic effects.
Small amounts of ethinyl estradiol and norgestimate pass into breast milk; may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding; alternative contraception recommended.
Contraindicated during breastfeeding due to potential for reduced milk production and excretion of estrogen/progestin into breast milk. M/P ratio: Not established.
No dosing adjustments applicable; drug is contraindicated during pregnancy. If used inadvertently, discontinue immediately.
No dosing adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic metabolism, volume of distribution) are not relevant due to contraindication.
Category C
Category C
Contains norgestimate 0.180/0.215/0.250 mg and ethinyl estradiol 0.035 mg. Triphasic regimen mimics natural cycle. Monitor for breakthrough bleeding, especially during first 3 cycles. Use with caution in patients with migraine with aura, hypertension, or history of VTE. Effective for acne vulgaris (FDA-approved indication). Counsel that efficacy may be reduced with concurrent rifampin, certain anticonvulsants, and St. John's wort. Consider switching to monophasic pill if persistent breakthrough bleeding after 3 months.
Monitor for thromboembolic events, especially in smokers over 35. Counsel about missed dose protocol: take as soon as remembered, use backup contraception if >12 hours late. Caution with hepatic enzyme inducers (e.g., rifampin, anticonvulsants) reducing efficacy. Check BP at baseline and periodically. Consider VTE risk with obesity or immobilization. Not for use in pregnancy or breastfeeding.
Take one pill daily at the same time for 21 days, then placebo pills for 7 days.If you miss a pill within 12 hours, take it as soon as remembered. If more than 12 hours late, use backup contraception (e.g., condoms) for 7 days.Do not smoke while taking this medication; smoking increases risk of blood clots and stroke, especially if over 35.Common side effects: spotting between periods, nausea, breast tenderness, headache. These often improve after a few cycles.Seek emergency medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, difficulty breathing, severe headache, vision changes.This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time, even if not sexually active.If you miss a dose, take it as soon as you remember; if more than 12 hours late, use backup contraception for 7 days.Smoking increases risk of serious cardiovascular side effects, especially in women over 35.Notify your doctor if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, or vision changes.This medication does not protect against HIV or other STDs.Inform all healthcare providers that you are taking this drug.